Britain’s Cancer Research Technology says the dire financing situation facing European biotechs has forced it to become a bridge builder between research-based Big Pharma and academia, an intermediary role that it expects to expand on as the search for new oncology drugs intensifies.
Britain’s Cancer Research Technology Ltd. says the dire financing situation facing European biotechs has forced it to become a bridge builder between research-based Big Pharma and academia, an intermediary role that it expects to expand on as the search for new oncology drugs intensifies.
Lack of funding in Europe for early-stage biotech companies has forced CRT, the technology transfer arm of the charity
The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.
S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
